申请人:Enanta Pharmaceuticals, Inc.
公开号:US20160159843A1
公开(公告)日:2016-06-09
The present invention discloses compounds of formula (I), or a pharmaceutically acceptable salt thereof:
which inhibit, preventing or treating abnormal cellular proliferation and/or a viral infection, particularly by HIV, HCV or HBV. Consequently, the compounds of the present invention interfere with the replication cycle of a virus and are also useful as antiviral agents, or interfere with host cellular biochemical process and are also useful as antiproliferative agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from viral infection and/or cell proliferation. The invention also relates to methods of treating a viral infection and/or cell proliferation in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention relates to novel antiviral/anti-proliferative compounds represented herein above, pharmaceutical compositions comprising such compounds, and methods for the treatment or prophylaxis of viral infection in a subject in need of such therapy with said compounds.
本发明揭示了式(I)的化合物或其药学上可接受的盐:它们能够抑制、预防或治疗异常的细胞增殖和/或病毒感染,特别是HIV、HCV或HBV感染。因此,本发明的化合物干扰病毒的复制周期,也可用作抗病毒药物,或干扰宿主细胞的生化过程,也可用作抗增殖药物。本发明还涉及包含上述化合物的制药组合物,用于治疗患有病毒感染和/或细胞增殖的受试者。本发明还涉及通过给受试者使用包含本发明化合物的制药组合物来治疗病毒感染和/或细胞增殖的方法。本发明涉及上述新型抗病毒/抗增殖化合物、包含这些化合物的制药组合物以及使用这些化合物治疗或预防受试者病毒感染的方法。